Tempus AI Inc. (NASDAQ:TEM) is a top stock in Cathie Wood’s portfolio, holding the ninth largest position with $579 million. Analysts increased price targets to $105 based on management’s focus on data and pharma business growth, Ambry Genetics success, and advanced algorithm solutions potential for high margins.

Morgan Stanley raised Tempus AI Inc.’s price target to $80, maintaining a Buy rating. The health technology company, which went public in 2024, utilizes AI to advance precision medicine. While showing investment potential, other AI stocks may offer greater upside with less downside risk.

Investors looking for undervalued AI stocks may find better opportunities elsewhere. An analyst suggests exploring other AI stocks with significant growth potential and benefits from current economic trends for better returns. For more stock recommendations, check out Insider Monkey’s curated lists of fantastic and hottest stocks to watch.

Read more at Yahoo Finance: Why Analysts See Long-Term Upside in Tempus AI (TEM)